Literature DB >> 21189378

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

Heinz-Josef Klümpen, Karla C S Queiroz, C Arnold Spek, Carel J M van Noesel, Helmy C Brink, Wendy W J de Leng, Roeland F de Wilde, Elisabeth M H Mathus-Vliegen, G Johan A Offerhaus, Maarten A Alleman, Anneke M Westermann, Dirk J Richel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21189378      PMCID： PMC4856022          DOI： 10.1200/JCO.2010.32.7825

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

2.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.

Authors:  D E Jenne; H Reimann; J Nezu; W Friedel; S Loff; R Jeschke; O Müller; W Back; M Zimmer
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

Review 3.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

Review 4.  High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.

Authors:  M G F van Lier; A Wagner; E M H Mathus-Vliegen; E J Kuipers; E W Steyerberg; M E van Leerdam
Journal:  Am J Gastroenterol       Date:  2010-01-05       Impact factor: 10.864

5.  Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.

Authors:  Chongjuan Wei; Christopher I Amos; Nianxiang Zhang; Xiaopei Wang; Asif Rashid; Cheryl L Walker; Richard R Behringer; Marsha L Frazier
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

6.  Lkb1 is required for TGFbeta-mediated myofibroblast differentiation.

Authors:  Kari Vaahtomeri; Eeva Ventelä; Kaisa Laajanen; Pekka Katajisto; Pierre-Jean Wipff; Boris Hinz; Tea Vallenius; Marianne Tiainen; Tomi P Mäkelä
Journal:  J Cell Sci       Date:  2008-10-07       Impact factor: 5.285

7.  LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis.

Authors:  Pekka Katajisto; Kari Vaahtomeri; Niklas Ekman; Eeva Ventelä; Ari Ristimäki; Nabeel Bardeesy; Robert Feil; Ronald A DePinho; Tomi P Mäkelä
Journal:  Nat Genet       Date:  2008-03-02       Impact factor: 38.330

8.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Authors:  Andrew J Wagner; Izabela Malinowska-Kolodziej; Jeffrey A Morgan; Wei Qin; Christopher D M Fletcher; Natalie Vena; Azra H Ligon; Cristina R Antonescu; Nikhil H Ramaiya; George D Demetri; David J Kwiatkowski; Robert G Maki
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

9.  Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Authors:  J-C Soria; F A Shepherd; J-Y Douillard; J Wolf; G Giaccone; L Crino; F Cappuzzo; S Sharma; S H Gross; S Dimitrijevic; L Di Scala; H Gardner; L Nogova; V Papadimitrakopoulou
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

10.  LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.

Authors:  Jennifer P Morton; Nigel B Jamieson; Saadia A Karim; Dimitris Athineos; Rachel A Ridgway; Colin Nixon; Colin J McKay; Ross Carter; Valerie G Brunton; Margaret C Frame; Alan Ashworth; Karin A Oien; T R Jeffry Evans; Owen J Sansom
Journal:  Gastroenterology       Date:  2010-05-06       Impact factor: 22.682
View more
  36 in total

1.  A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Authors:  Lu Chen; Brienne E Engel; Eric A Welsh; Sean J Yoder; Stephen G Brantley; Dung-Tsa Chen; Amer A Beg; Chunxia Cao; Frederic J Kaye; Eric B Haura; Matthew B Schabath; W Douglas Cress
Journal:  J Thorac Oncol       Date:  2016-02-23       Impact factor: 15.609

Review 2.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 3.  Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.

Authors:  Helena Verdaguer; Tamara Saurí; Teresa Macarulla
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 4.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Authors:  Ignacio Garrido-Laguna; Manuel Hidalgo
Journal:  Nat Rev Clin Oncol       Date:  2015-03-31       Impact factor: 66.675

Review 5.  Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?

Authors:  Namrata Vijayvergia; Steven J Cohen
Journal:  J Gastrointest Oncol       Date:  2016-10

6.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Authors:  Emmet J Jordan; Hyunjae R Kim; Maria E Arcila; David Barron; Debyani Chakravarty; JianJiong Gao; Matthew T Chang; Andy Ni; Ritika Kundra; Philip Jonsson; Gowtham Jayakumaran; Sizhi Paul Gao; Hannah C Johnsen; Aphrothiti J Hanrahan; Ahmet Zehir; Natasha Rekhtman; Michelle S Ginsberg; Bob T Li; Helena A Yu; Paul K Paik; Alexander Drilon; Matthew D Hellmann; Dalicia N Reales; Ryma Benayed; Valerie W Rusch; Mark G Kris; Jamie E Chaft; José Baselga; Barry S Taylor; Nikolaus Schultz; Charles M Rudin; David M Hyman; Michael F Berger; David B Solit; Marc Ladanyi; Gregory J Riely
Journal:  Cancer Discov       Date:  2017-03-23       Impact factor: 39.397

Review 7.  Luminal breast cancer: from biology to treatment.

Authors:  Michail Ignatiadis; Christos Sotiriou
Journal:  Nat Rev Clin Oncol       Date:  2013-07-23       Impact factor: 66.675

Review 8.  New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.

Authors:  Helena Verdaguer; Alvaro Arroyo; Teresa Macarulla
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

9.  Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Authors:  Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Ali Amin-Mansour; Amaro Taylor-Weiner; Mara Rosenberg; Nathanael Gray; Justine A Barletta; Yanan Guo; Scott J Swanson; Daniel T Ruan; Glenn J Hanna; Robert I Haddad; Gad Getz; David J Kwiatkowski; Scott L Carter; David M Sabatini; Pasi A Jänne; Levi A Garraway; Jochen H Lorch
Journal:  N Engl J Med       Date:  2014-10-09       Impact factor: 91.245

10.  Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Authors:  Cheyennedra C Bieg-Bourne; Sherri Z Millis; David E Piccioni; Paul T Fanta; Michael E Goldberg; Juliann Chmielecki; Barbara A Parker; Razelle Kurzrock
Journal:  Cancer Res       Date:  2017-09-22       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.